Indeed, HCC variants with β-catenin pathway activation exhibit significantly reduced CD8-positive T cell infiltration and PD-L1 expression, suggesting diminished responsiveness to PD-1/PD-L1 antibody therapies. This evidence concerns the gene CD8A and hepatocellular carcinoma.